DUBLIN–(BUSINESS WIRE)–The “Kidney Cancer Drugs Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering.
The global kidney cancer drugs market was valued at about $3.3 billion in 2018 and is expected to grow to $3.95 billion at a CAGR of 4.6% through 2022.
The kidney cancer drugs market consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy.
North America was the largest region in the kidney cancer drugs market in 2018, followed by Asia Pacific and Europe. The kidney cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.
Rise in incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Change in lifestyle of people, consumption of tobacco and unhealthy diet are some factors which contribute to the growth of these renal cancer cells. According to American Cancer Society Report 2018, an estimated 65,340 new cases of kidney (renal) cancer were diagnosed in the US in 2018 and in 2014, the estimation was around 63,920 new cases. Thus, driving the growth of the kidney cancer drugs market.
Increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective. Also, targeted drugs are used post kidney cancer surgery to prevent re-occurrence of kidney cancer. Conventional chemical drugs cannot be used in the same way.
Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials. In a study conducted by Pfizer, using targeted therapy had more chances of tumor shrinkage than using chemical drugs. Targeted drug, axitinib and Pembrolizumab are being used to treat stage IV kidney cancer which specially attacks the spreading points of cancer. Thus, pharmaceutical industry is embracing the targeted therapies because of the above-mentioned benefits. Therefore, hindering the growth of the kidney cancer drugs market.
Use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer resistant cells from developing. The improved understanding about renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of mammalian target of rapamycin (mTor), which helps promote cellular biogenesis.
According to a study conducted by National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in the patients suffering from advanced kidney cancer. In April 2019, Merck attained food and drug administration (FDA) approval to combine their drug Pembrolizumab, which enhances the patients’ immune system along with Pfizer’s drug Axitinib, which prevents the spread of renal cancer, this combination of drugs can help increase the pace of the patients’ recovery in advanced kidney cancer.
The kidney cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA’s recommendation for kidney cancer drugs industry in the form of guidelines are mentioned within the CFR ‘s (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part ‘A’ to sub part ‘I’. The sub-part ‘E’ deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer.
The sub part ‘E’ also includes guidelines for the monitoring and evaluation of clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in kidney cancer drugs industry are required to abide to the regulations under FDA.
In October 2018, Novartis International AG, a Swiss multinational pharmaceutical company acquired Endocyte for $2.1 billion. With this acquisition, Novartis will expand Radioligand Therapy (RLT) platform with both a potential near-term product launch and early-stage clinical development programmes. Endocyte, a US-based biopharmaceutical company develops targeted therapies for the treatment of cancer and inflammatory diseases.
Major players in the market are Bayer AG, Pfizer Inc, Novartis International AG, Exelixis, Inc, F. Hoffmann-La Roche Ag
- Markets Covered: 1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC) 2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Others 3) By End Users: Hospitals, Clinics, Research Center, Others
- Companies Mentioned: Bayer AG, Pfizer Inc, Novartis International AG, Exelixis, Inc, F. Hoffmann-La Roche Ag
- Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
- Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
- Time Series: Five years historic and forecast.
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Genentech Inc.
- Glaxosmithkline Plc
- Active Biotech
- Thermo Fisher Scientific Inc
- Bristol-Myers Squibb
- Cipla Limited
- Abbott Laboratories
- Aveo Pharmaceuticals
- Immatics Biotechnologies
- Prometheus Laboratories
- Argos Therapeutics
- Myriad Genetics Inc
- NeoGenomics Laboratories
- NanoString Technologies Inc
- Sysmex Corporation
- Rosetta Genomics
- Illumina Inc
- Quest Diagnostics Incorporated
For more information about this report visit https://www.researchandmarkets.com/r/o09nn8
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900